Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

NCT01366534 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria

Interventions

BIOLOGICAL: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)
BIOLOGICAL: GSK Biologicals' malaria vaccine 257049 (2 doses)
BIOLOGICAL: GSK Biologicals' malaria vaccine 257049 (3 doses)
OTHER: Sporozoite challenge

Sponsor

GlaxoSmithKline

Collaborators

[object Object]
[object Object]